Inside Science Corp's $400M Series D: The Engineering and Regulatory Architecture of the PRIMA BCI

An architectural and financial breakdown of Science Corp's $400M Series D round at a $3.5B valuation, detailing PRIMA's subretinal photovoltaic array, the FDA HDE pathway, and biohybrid BCI horizons.

Published: 2026.11.18

Series D Capitalization
$400M raised

Post-money valuation reaches $3.5B led by Khosla Ventures

Optical Resolution
378 micro-electrodes

Wireless photovoltaic subretinal transduction array

US Commercial Window
Early 2027

Targeted market entry via FDA Humanitarian Device Exemption

Executive Takeaway ·By prioritizing wireless subretinal photovoltaics over invasive intracortical craniotomies, Science Corp establishes an immediate European and US commerci…

Science Corp has closed a $400 million Series D financing round, establishing a $3.5 billion valuation. Led by Khosla Ventures, the syndicate includes the Ackman Oxman Institute, Tenet Healthcare, 885 Capital, Y Combinator, and PLC Neurotech. The capital allocation targets two distinct horizons: scaling clinical and commercial operations for PRIMA—a subretinal photovoltaic neuroprosthetic—and funding first-in-human trials for its next-generation Biohybrid cortical platform.

Founded by former Neuralink CEO Max Hodak, Science Corp is diverging from the high-trauma intracortical arrays favored by competitors. Rather than pursuing full craniotomies for broad-spectrum motor decoding, the company has deployed a commercial medical hardware stack that leverages existing ophthalmic surgical protocols. This technical and commercial posture minimizes regulatory friction while unlocking rapid clinical adoption across European and North American healthcare systems.

PRIMA Optical-to-Neural Transduction Pipeline

Signal processing chain from photon capture to optic nerve stimulation

01 · Step 01
1. Ambient Capture & Glare Filtering

Forward-facing camera in glasses samples scene; internal DSP strips high-intensity ambient solar noise.

02 · Step 02
2. Near-Infrared Projection

Integrated micro-projector collimates structured near-infrared (NIR) patterns into the patient pupil.

03 · Step 03
3. Photovoltaic Transduction

Subretinal 378-electrode array converts incident NIR photons directly into local electrical potentials.

04 · Step 04
4. Bipolar Cell Activation

Current pulses bypass degenerate photoreceptors to depolarize intact retinal bipolar and ganglion networks.

Photovoltaic Retinal Architecture: Signal Transduction Without Trans-Scleral Cabling

PRIMA addresses advanced geographic atrophy secondary to age-related macular degeneration (AMD). Degenerative ocular conditions selectively destroy outer retinal photoreceptor cells while leaving inner nuclear layer cells, including bipolar and horizontal neurons, functionally intact. PRIMA bypasses the missing photoreceptive layer by converting structured near-infrared (NIR) light directly into localized electrical fields.

The hardware architecture consists of a subretinal micro-implant measuring two millimeters across and thirty micrometers thick. The silicon matrix houses 378 independent pixels, each equipped with its own integrated photodiode and central platinum-iridium stimulation electrode. The pixels operate passively: incident NIR light generates sufficient local current to depolarize adjacent retinal interneurons without requiring onboard batteries, internal RF induction coils, or physical power cables penetrating the sclera.

External processing is handled by custom sensor glasses. A forward-facing digital sensor captures the visible field of view, applies dynamic range compression to remove sunlight artifacts, and converts optical scenes into pulse-width-modulated infrared frames. These frames are projected directly through the ocular media onto the subretinal chip. Because stimulation frequency and pulse duration are modulated by the projector, the implant’s stimulation parameters can be adjusted via software updates without requiring secondary revision surgery.

Neural Interface Deployment Paradigms

Subretinal photovoltaic array versus intracortical penetrating array

High Surgical Trauma
Invasive Intracortical (e.g., Neuralink N1)
  • • Requires full craniotomy and robotic dural penetration
  • • Active transcutaneous RF inductive recharging loops
  • • Long-term glial scarring and electrode encapsulation risks
  • • Multi-year FDA IDE pivotal trial horizons
Outpatient Ophthalmic
Subretinal Photovoltaic (Science PRIMA)
  • • Standard 2-hour pars plana vitrectomy procedure
  • • Zero internal power supply; passive NIR photovoltaic powering
  • • Encapsulation isolated away from the cerebral cortex
  • • Expedited FDA Humanitarian Device Exemption pathway
Verdict ·PRIMA trades broader motor-cortex decoding for an immediate, lower-risk outpatient surgical profile.

Hardware and Regulatory Matrix: Science Corp vs. Enterprise BCI Architectures

Medical neural interfaces diverge significantly across implantation complexity, regulatory approval tracks, and manufacturing overhead. Science Corp’s tactical bifurcation—deploying the targeted PRIMA platform for rapid revenue generation while developing its Biohybrid platform for long-term deep-brain targets—contrasts with the monolithic platforms pursued across the neurotechnology sector.

Feature / MetricScience Corp (PRIMA)Neuralink (N1 System)Synchron (Stentrode)
Target Anatomical SiteSubretinal space (Eye)Motor cortex (Cerebrum)Superior sagittal sinus (Vascular)
Surgical ProcedureOutpatient vitrectomyStereotactic robotic craniotomyMinimally invasive endovascular
Physical Channel Count378 active electrodes1,024 microwire electrodes16 stent-mounted electrodes
Power InfrastructurePassive photovoltaic (NIR)Subcutaneous battery + RF chargingInductive telemetry unit
Primary IndicationGeographic atrophy / AMDSevere quadriplegia / ALSSevere paralysis / Communication
Current Clinical StatusCE mark pathway / FDA HDEFDA IDE human feasibility trialsFDA IDE pivotal trials
Estimated Device TCO$85,000–$120,000 (Targeted)$150,000–$250,000+ (Simulated)$110,000–$160,000 (Simulated)

Science Corp is advancing PRIMA in the United States through the FDA’s Humanitarian Device Exemption (HDE) regulatory pathway. The HDE mechanism provides a streamlined approval process for devices targeting conditions affecting fewer than 8,000 individuals in the US annually. While geographic atrophy impacts millions globally, Science Corp’s initial regulatory focus is on severe, bilateral end-stage photoreceptor loss. This narrow indication drastically reduces trial cohort size and clinical trial timeline requirements compared to standard Premarket Approval (PMA) applications, targeting commercial availability in early 2027.

In Europe, the clinical rollout is already operational. Patient procedures are underway in Germany, with regulatory clearances pending in Italy, France, and the United Kingdom. To capture immediate high-margin revenue, Science Corp is establishing a private self-pay clinical unit at Moorfields Private Eye Hospital in London. This dual-track reimbursement approach—private out-of-pocket centers in premium European hubs paired with public health system coverage across Germany—hedges against protracted government reimbursement reviews.

Regulatory and Surgical Timeframe Differentials

Clinical path duration from pilot protocol to initial commercial distribution

Invasive Intracortical Systems PRIMA Photovoltaic System
Surgical Duration 60% less OR time
Invasive Intracortical Systems 4.5 hours
PRIMA Photovoltaic System 1.8 hours
FDA Approval Cycle Up to 5 years faster
Invasive Intracortical Systems 7–9 years (PMA)
PRIMA Photovoltaic System 3–4 years (HDE)
Post-Operative Inpatient Stay Same-day discharge
Invasive Intracortical Systems 48–72 hours
PRIMA Photovoltaic System 0–4 hours (Outpatient)

The Biohybrid Interface: Bridging Silicon and Cultured Cortical Tissue

While PRIMA drives near-term commercial execution, Science Corp’s long-term enterprise valuation hinges on its proprietary Biohybrid architecture. Traditional microelectrode arrays suffer from progressive signal attenuation caused by foreign body responses, neuroinflammation, and reactive astrogliosis. Rigid silicon and metal shanks mechanically mismatch soft brain parenchyma, provoking cellular encapsulation that degrades chronic signal-to-noise ratios.

Mitigating Chronic BCI Signal Degradation

Biohybrid resolution to the cortical foreign body response

01 · Inherent Failure Mode
Mechanical Shear & Glial Scarring

Rigid metal electrodes micro-tear brain tissue, triggering astrocyte proliferation that insulates recording pins within 12–24 months.

02 · Structural Mechanism
Living Cellular Intermediary

Lab-cultured neural tissue is grown directly on a silicon array, creating a biological bridge between microchips and native cerebral circuits.

03 · Clinical Resolution
Endogenous Synaptic Integration

Implanted cultured neurons extend functional axons into the recipient cortex, stabilizing long-term chronic connectivity.

The Biohybrid program combines synthetic microelectronics with living cellular substrates. Science Corp cultures biological neurons directly onto high-density CMOS sensor matrices in vitro, establishing functional synaptogenesis between the living cells and metallic recording nodes before implantation. When surgically integrated into cerebral tissue, the biological layer integrates with native circuits via axonal sprouting, while the underlying silicon substrate reads and drives neural signaling.

To direct clinical translation, Science Corp recruited Yale neurosurgery professor Murat Günel. Animal studies have confirmed viable biohybrid integration, with the company projecting first-in-human clinical trials within the next 16 months. Initial indications target neurodegenerative conditions, including Parkinson’s disease, where conventional deep brain stimulation (DBS) fails to provide closed-loop, cell-specific therapeutic intervention.

Science Corp Strategic Execution Horizon (2026–2028)

Dual-track deployment across commercial retinal arrays and biohybrid trials

Q4 2026
Series D Capital Deployment

Close $400M round; expand German ophthalmic centers and launch Moorfields private self-pay unit.

H1 2027
US HDE Commercial Approval

Secure FDA Humanitarian Device Exemption clearance for bilateral end-stage AMD cases.

Mid-2027
Biohybrid First-in-Human Trials

Initiate clinical protocol led by Yale Neurosurgery for chronic neurodegenerative motor disorders.

2028
Indication Expansion

Scale PRIMA manufacturing to initiate clinical pivotal trials for Stargardt's disease and retinitis pigmentosa.

Capital Allocation and Enterprise Risk Analysis

Science Corp’s capitalization alters the operational calculus for high-tier medical hardware ventures. The primary risk vectors confronting institutional stakeholders require ongoing capital governance:

  • Ophthalmic Yield and Manufacturing Throughput: Photovoltaic subretinal chips require sub-micron precision to maintain electrode integrity across cleanroom fabrication cycles. Manufacturing defects that lower active electrode yields below 90% directly degrade projected visual acuity, presenting real-world supply chain risks as demand scales across multiple European jurisdictions.
  • HDE Reimbursement Limitations: The FDA’s Humanitarian Device Exemption path carries restrictions on commercial pricing structures and annual patient caps. Science Corp must balance early market clearance against constrained unit margins, necessitating rapid indication expansion into Stargardt’s disease to scale domestic procedure volume.
  • Biohybrid Biological Longevity: Integrating live tissue with CMOS circuits introduces major storage, preservation, and shelf-life complexities. Clinical sites must manage fragile, living biological products rather than inert, shelf-stable titanium implants, requiring strict cold-chain infrastructure and standardized operating-room handling protocols.

Science Corp’s $400 million capitalization provides sufficient liquidity to establish commercial infrastructure across Europe and the US while shielding its biohybrid development pipeline from mid-stage capital crunches. If PRIMA secures its targeted early 2027 FDA approval, the company will achieve operational cash generation years ahead of pure-play cerebral BCI competitors, validating its pragmatic approach to neural interface commercialization.

Related Benchmark Reports

View All in Category →
Weekly Briefing

Weekly Tech & Business Data Briefing

Verified software analysis, practical gotchas, and essential supply-chain updates delivered weekly.

Unsubscribe with 1 click anytime. Zero spam.

* We may earn an affiliate commission from links in this report, at no extra cost to you and with zero impact on our benchmark data.